Result:Weak· Market: Crashed#Margin squeeze
| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 125.95 | 49.3% | 0.6% |
| Total Income | 125.99 | 49.3% | 0.6% |
| Expenditure | 127.45 | 47.5% | 1.9% |
| PBT | -1.45 | 125.9% | 186.8% |
| Net Profit | -1.67 | 195.7% | 199.7% |
| OPM | 0.43% | 3.34pp | 1.51pp |
| NPM | -1.32% | 2.02pp | 2.64pp |
| EPS | 0.31 | 22.5% | 18.4% |
Pharma manufacturer swung to a net loss with revenue roughly flat YoY (-0.6%) and OPM compressing sharply from 1.94% to 0.43%, indicating core-business deterioration rather than a one-off.
Informational and educational content only. Not investment advice.